Deontics, a medtech spin-out of Oxford University, has secured a £700,000 ($1.15m) investment. Investors include John McMonigall, former head of technology investments at venture capital firm Apax Partners.
Based on ten years of research by John Fox at Oxford’s Engineering Department, the company commercialises software that creates personalised treatment guides for patients by analysing all relevant scientific and clinical information.
The technology is already in use at the Royal Free Hospital in London, where it supported the treatment of several thousand patients suffering from breast cancer. It will now also be rolled out at an unnamed US national and international hospital chain.
The original research was funded by Cancer Research UK, University College London, the Royal Free Charity as well as Oxford University. As part of his investment, John McMonigall will now join the spin-out as chairman.
John Fox, professor at Oxford University, said: “Patient safety and improving patient outcomes are at the heart of why we developed this software. All patients should have access to healthcare guided by the very latest scientific and clinical evidence. We would like to give all doctors the tools and information to make best-practice decisions for each and every patient, ensuring that even patients in the most remote areas receive gold-standard treatment. Our software will also give patients information that doctors have, in a lay format.”
